PMH43 DECLINE IN THE RATE AND COST OF PSYCHIATRIC HOSPITALIZATION FOLLOWING INITIATION OF DEPOT ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA  by Peng, X et al.
A112 Abstracts
costs than women, but differences in other cost items were not signiﬁcant. The mean 
age was 51 years (SD 14 years) and 54% (SD 0.50) were men. CONCLUSIONS: As 
the societal costs for patients with schizophrenia are high and strongly related to global 
functioning, attempts to improve functioning by means of effective treatment and 
rehabilitation might not only decrease suffering for patient’s and relatives, but also 
reduce societal cost of illness.
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OBJECTIVES: While the economic costs of substance abuse have been extensively 
examined in the published literature, information on the costs of abuse of prescription 
opioids is more limited, despite this rapidly growing problem in the US. The National 
Survey of Drug Use and Health (NSDUH) estimated that, between 2001 and 2006, 
the number of persons using prescription pain relievers for nonmedical purposes 
increased from 3.5 million to 5.2 million. We sought to estimate the economic burden 
of prescription opioid abuse in the US. METHODS: We estimated the current eco-
nomic burden of prescription opioid abuse in the US in terms of direct substance abuse 
treatment, medical complications, productivity loss, and criminal justice. Utilizing 
information from NSDUH, we distributed our broad cost estimates among the various 
drugs of abuse, including prescription opioids, down to the individual drug level. Data 
sources included the National Expenditures for Mental Health Services and Substance 
Abuse Treatment; the CDC’s mortality database and HIV/AIDS Surveillance Report; 
the Ofﬁce of National Drug Control Policy’s estimates of the economic costs of drug 
abuse in the US; the US DOJ’s Uniform Crime Statistics, proﬁles of prison and jail 
inmates and expenditure and employment reports; and the published literature. 
RESULTS: The estimated 2006 total cost of prescription opioid abuse was $53.4 
billion, of which $42 billion (79%) was attributable to productivity loss, $8.2 billion 
(15%) to criminal justice costs, $2.2 billion (4%) to abuse treatment, and $944 million 
to medical complications (2%). In our analysis of costs by speciﬁc prescription opioids, 
ﬁve drugs—OxyContin, oxycodone, hydrocodone, propoxyphene, and methadone—
accounted for two thirds of all prescription-opioid-attributable costs. CONCLU-
SIONS: The great majority of the economic costs of opioid abuse, 94%, are accounted 
for by lost productivity and crime. The burden of prescription opioid abuse in the US 
is high and will likely continue to grow.
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OBJECTIVES: Antipsychotics in long-acting formulations (“depot”) are often tar-
geted for patients with schizophrenia who are at high risk of relapse and hospitaliza-
tion. Little information is available on the change in the rate or cost of psychiatric 
hospitalization following the initiation of depot antipsychotics. This retrospective 
mirror-image study used a U.S. health insurance claims database to assess changes in 
the rate, duration, and cost of psychiatric hospitalizations following initiation of long-
acting (depot) antipsychotics in patients with schizophrenia. METHODS: Patients 
younger than 65 who were diagnosed with schizophrenia on at least 2 outpatient visits 
or 1 inpatient hospitalization were identiﬁed from a U.S. commercial database 
(January 1, 2004 to March 1, 2008). Patients started on a depot antipsychotic (no 
depot injection in the prior 6 months) were studied in a “mirror image” design to 
assess change in psychiatric hospitalization rates, the mean duration and cost of 
hospitalization between the 6 months prior versus 6 months post medication initiation. 
Cost comparisons were conducted with paired t-test and bootstrapping methods. 
RESULTS: A total of 147 patients with schizophrenia were in the analysis. Compared 
to the six months prior to depot initiation, the rate of psychiatric hospitalization in 
the six months post-initiation declined from 49.7% to 22.5% (p < 0.001); the mean 
hospitalized duration for psychiatric purposes numerically declined from 7.3 to 4.7 
days (p = 0.08). The change in total health care costs declined from $11,111 to $7,884 
and was driven by the reduction in costs for psychiatric hospitalizations from $5,384 
to $2,537 (cost offset of $-2,847). CONCLUSIONS: The initiation of depot antipsy-
chotic therapy appears to be associated with declines in hospitalization rates and 
hospitalization costs. Current ﬁndings suggest that treatment with depot antipsychot-
ics is a cost-effective option for a subgroup of patients with schizophrenia who are at 
high risk of nonadherence with their oral antipsychotic medication regimen.
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OBJECTIVES: Investigate the relationship between persistence with antipsychotic 
drug therapy and treatment costs in patients with schizophrenia. METHODS: A 
retrospective database study was performed using Medi-Cal data from 1994 to 2003. 
Patients with schizophrenia were identiﬁed using ICD-9 codes. A total of 238,754 
episodes of psychotropic drug therapy were used to estimate a series of ordinary least 
squares (OLS) regression models of post-treatment cost as a function of alternative 
deﬁnitions of persistence. All models adjusted for baseline independent variables 
including demographics, drug use history, prior medical care use and co-morbid 
medical conditions. RESULTS: Our primary model compared ‘gold standard’ persis-
tence patients [deﬁned as achieving one year of continuous therapy with no augmenta-
tion or switching] to other classiﬁcations of persistent and non-persistent behavior. 
The least expensive patients were quitters [-$1484] and patients who use their initial 
medication intermittently [-$1791] primarily due to having lower drug costs. Patients 
who were persistent on their initial drug while adding a second drug and patients who 
achieved one year of persistence on their added drug were signiﬁcantly more costly to 
treat than ‘gold standard’ patients [+$1935 and +$3185, respectively] [p < 0.0001 for 
all estimates]. CONCLUSIONS: These results suggest that the intermittent use of 
psychotropic medications may be a cost-effective treatment strategy for some patients. 
However, low cost and intermittent use may also indicate that the patient has with-
drawn from contact with the health care system. Conversely, patients who experience 
costly, sub-optimal outcomes may tend to add or switch drugs while maintaining 
uninterrupted therapy. Clearly, using persistence as a measure of drug performance 
in comparative effectiveness research may be misleading without data on switching 
and severity of illness. As a result, medications used to treat more severe patients may 
appear to be the most expensive medications when compared head-to-head with 
medications used to treat intermittent therapy patients.
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OBJECTIVES: Health plans monitor daily dosing of pharmaceuticals by calculating 
daily average consumption (DACON) and average daily cost ($ADC) on the basis of 
aggregate pharmacy data We examined DACON and $ADC for duloxetine-treated 
patients with 1 or more disorders for which duloxetine has received FDA approval. 
METHODS: This retrospective analysis examined US commercially insured patients 
who received ≥1 prescription of duloxetine during 2008 for 1 or more of the following 
disorders: major depressive disorder (MDD), diabetic peripheral neuropathic pain 
(DPNP), generalized anxiety disorder (GAD), or ﬁbromyalgia (FM). Patients were 
assigned to subgroups by indication based on diagnosis codes recorded during the 12 
months prior to their ﬁrst recorded duloxetine prescription during the study interval. 
DACON was calculated by dividing total pills dispensed by total days of supply. 
$ADCs were calculated using June 2009 new wholesale prices. RESULTS: There were 
47,089 duloxetine-treated patients from 2008 included in the analysis, 28,313 with 
diagnosed MDD, 16,285 with FM, 5,769 with GAD, and 2,575 with DPNP. Overall 
DACON for duloxetine among all patients was 1.34 capsules per day, and $ADC was 
$5.44. For duloxetine-treated patients with MDD only (no GAD, DPNP, or FM), 
DACON and $ADC were 1.42 and $5.62, respectively. For patients with FM only, 
DACON/$ADC were 1.28/$5.10; for GAD only, 1.25/$4.96; and for DPNP only, 
1.25/$4.99. DACON and $ADC were higher among patients with both MDD and 
another indicated disorder: 1.52/$6.06 for MDD and FM; 1.47/$5.85 for MDD and 
GAD, and 1.50/$5.98 for MDD and DPNP. CONCLUSIONS: DACON and $ADC 
for duloxetine were higher for patients with MDD alone than for patients with GAD, 
DPNP, or FM alone. DACON and $ADC were somewhat higher for patients with 
MDD and another indicated disorder than for MDD alone, though there was little 
variation in these measures with respect to which indication MDD was paired.
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OBJECTIVES: Treatment adherence for a sufﬁcient duration is important in the treat-
ment of major depressive disorder (MDD). This study examined the association 
between treatment persistence with duloxetine and health care costs in the year after 
medication initiation. METHODS: In a large U.S. commercial managed-care claims 
database, 4542 patients (18 to 64 years old) with at least 1 claim with a diagnosis of 
MDD (ICD-9-CM: 296.2 and 296.3) were initiated on duloxetine during 2006. 
Patients were included if they had no active prescription of duloxetine during the 6 
months prior to initiation and had continuous enrollment for 12 months prior to and 
post-duloxetine initiation. Treatment persistence was deﬁned as the length of therapy 
without exceeding a 30-day gap. A general linear model regression was performed to 
examine the associations between treatment persistence and health care costs in the 
post 1 year. RESULTS: Overall, average length of duloxetine therapy was 116.0 days 
(SD = 63.5) in the post 6 months; 62.8% of patients stayed on the medication for 
more than 3 months. Signiﬁcant associations between persistence and health care costs 
were observed. With prolonged length of therapy (<31 days, 31–90 days, >90 days), 
average total health care costs were signiﬁcantly reduced ($25,499, $18,438, and 
$17,255, p = .020). Speciﬁcally, medical costs were signiﬁcantly reduced ($21,338, 
$14,123, and $11,496, p = 0.009), while pharmacy costs were increased ($4,161, 
$4,316, and $5,759, p < 0.001). After adjustment for baseline demographics, comor-
bid conditions, and health care costs, results were essentially unchanged. Adjusted 
total health care costs were $20,162, $13,821, and $13,706 for patients who stayed 
on the medication for <31 days, 31–90 days, and >90 days, respectively. CONCLU-
